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Abstract
Background: Transcription factor 4 (TCF4 alias ITF2, E2-2, ME2 or SEF2) is a ubiquitous class A basic helix-loop-helix protein
that binds to E-box DNA sequences (CANNTG). While involved in the development and functioning of many different cell
types, recent studies point to important roles for TCF4 in the nervous system. Specifically, human TCF4 gene is implicated in
susceptibility to schizophrenia and TCF4 haploinsufficiency is the cause of the Pitt-Hopkins mental retardation syndrome.
However, the structure, expression and coding potential of the human TCF4 gene have not been described in detail.
Principal Findings: In the present study we used human tissue samples to characterize human TCF4 gene structure and
TCF4 expression at mRNA and protein level. We report that although widely expressed, human TCF4 mRNA expression is
particularly high in the brain. We demonstrate that usage of numerous 59 exons of the human TCF4 gene potentially yields
in TCF4 protein isoforms with 18 different N-termini. In addition, the diversity of isoforms is increased by alternative splicing
of several internal exons. For functional characterization of TCF4 isoforms, we overexpressed individual isoforms in cultured
human cells. Our analysis revealed that subcellular distribution of TCF4 isoforms is differentially regulated: Some isoforms
contain a bipartite nuclear localization signal and are exclusively nuclear, whereas distribution of other isoforms relies on
heterodimerization partners. Furthermore, the ability of different TCF4 isoforms to regulate E-box controlled reporter gene
transcription is varied depending on whether one or both of the two TCF4 transcription activation domains are present in
the protein. Both TCF4 activation domains are able to activate transcription independently, but act synergistically in
combination.
Conclusions: Altogether, in this study we have described the inter-tissue variability of TCF4 expression in human and
provided evidence about the functional diversity of the alternative TCF4 protein isoforms.
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Introduction
TCF4 (Gene 6925), alias ITF2 (immunoglobulin transcription
factor 2), SEF2 (leukemia virus SL3-3 enhancer factor 2), E2-2 and
ME2 (mouse E2), is one of the widely expressed class A basic helix-
loop-helix (bHLH) transcription factors (TFs) that are homologous
to Drosophila melanogaster protein daughterless (Gene 34413) [1,2].
ThebHLHfactor TCF4discussed hereshouldnotbe confused with
the high mobility group box transcription factor 7-like 2 (TCF7L2;
Gene 6934) that is a downstream effector of the b-catenin signaling
pathway and is also known as TCF4 (T-cell specific factor 4).
Class A bHLH factors in mammal si n c l u d eT C F 4 ,H E B( T C F 1 2 ;
Gene 6938) and E2A (TCF3, ITF1; Gene 6929) alternative isoforms
E12 and E47 [3]. These proteins are referred to as E-proteins since
they bind to Ephrussi box (E-box) sequence (CANNTG) as
homodimers or as heterodimers with tissue-specific bHLH factors
[3,4]. Dimerization is mediated by the C-terminal HLH motif that
together with the preceding stretch of basic amino acids is required
also for DNA binding. Structurally related Id proteins (inhibitors of
differentiation) hinder DNA binding of E-proteins by heterodimeriza-
tion, whereas Ca
2+-calmodulin specifically inhibits DNA binding of E-
protein homodimers [5–7]. Three amino-terminally distinct TCF4
isoforms have been described – TCF4-A, TCF4-B and TCF4-D [2].
All these isoforms contain the bHLH domain and a transcription
activation domain (AD2) [8]. TCF4-B has an additional transcription
activation domain in its N-terminus (AD1) [9].
In Drosophila the only E-protein, daughterless, is involved in
sex determination and neurogenesis [10,11]. In mammals,
substantial functional overlap among E-proteins has hampered
deciphering their exact roles. However, it is known that TCF4 is
required for postnatal survival in mice [12,13] and has many cell
lineage specific functions. For instance, TCF4 regulates develop-
ment of B-, T- and plasmacytoid dendritic cells [13–15],
development of Sertoli cells [16] and pontine nucleus neurons
[17], myogenesis [18], melanogenesis [19] and epithelial-mesen-
chymal transition [20]. The importance of TCF4 in human
nervous system development is underscored by the association of a
TCF4 allele with schizophrenia [21] and identification of TCF4
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22138haploinsufficiency as the cause for Pitt-Hopkins syndrome (OMIM
610954), a rare disease featuring mental retardation, hyperventi-
lation and seizures [22–24].
In this study we show that TCF4 is widely, but not equally
expressed and its levels are particularly high in the nervous system.
We demonstrate that usage of alternative 59 exons for transcribing
the human TCF4 gene potentially yields in numerous TCF4
protein isoforms that differ in their subcellular localization and
capacity to activate transcription.
Results
TCF4 gene contains many mutually exclusive 59 exons
To describe the structure and alternative splicing of the human
TCF4 gene we performed bioinformatic analysis of mRNA and
expressed sequence tag (EST) sequences available in public
databases and sequences of RT-PCR products from this study.
In estimation of transcription start sites we relied on publicly
available data from sequencing of oligo-cap, cap-trapping and
SMART cDNA libraries [25–28]. TCF4 gene is located on
chromosome 18q21.2 and spans 437 kbs. It has 41 exons of which
21 are alternative 59 exons situated at various positions throughout
the gene (Figure 1). In this study TCF4 exons are named as follows:
initial 59 exons are designated with a lowercase letter preceded by
a number that shows the following internal exon in the gene;
internal exons are numbered from 1 to 20; exon 21 is the only
terminal 39 exon. TCF4 transcripts are named according to the
initial exon they contain. Initial exons 1a and 1b are located
upstream of internal exon 1. Exons 3a–3d precede and 4a–4c
follow internal exon 3. 4c is a 59 extension of internal exon 4.
There are three 59 exons (5a–5c) in front of exon 5; two (7a, 7b) in
front of exon 7; four (8a–8d) in front of exon 8; and three (10a–
10c) in front of exon 10. Generally, 59 exons are spliced together
with the next internal exon in the gene, apart from the cases when
the following internal exon is a cassette exon and can be skipped
(exons 1 or 2, exon 3, exons 8–9; see below). As an exception 59
exon 1a is never used together with internal exons 1 or 2 and is
always joined to internal exon 3 or 4. We identified several
alternative splice donor sites in the 59 exons: two (I–II) in exons 5a,
8b and 8c; three (I–III) in exons 4a and 7a. In case of exon 7b the
intron between 7b-I and internal exon 7 can be retained giving rise
to 7b-II transcripts. Different usage of splice sites sometimes affects
the coding potential of a transcript (Figure 1C). In addition, the
reading frame shifts with alternative splicing of internal cassette
exons 1 or 2 and exon 3. Examination of open reading frames and
search for possible translation start codons demonstrated that,
altogether, TCF4 transcripts potentially code for 18 N-terminally
distinct protein isoforms named TCF4-A – TCF4-R (Figures 1C
and S1) of which only isoforms TCF4-A, TCF4-B and TCF4-D
have been described previously as SEF2-1A or ITF2-A, SEF2-1B
or ITF2-B, and SEF2-1D, respectively [2,18]. Most of the TCF4
isoforms have a stretch of unique amino acids in their N-termini
and the whole aminoterminal transactivation domain AD1 (coded
by exons 3–6) is present only in isoforms with the longest N-
termini such as TCF4-J, -K, -L and TCF4-B (Figures 1C and S1).
Other TCF4 isoforms contain parts of AD1 or are completely
devoid of it. More precisely, isoforms TCF4-C, -E, -M, -O and -P
contain a region of AD1 coded by exons 4–6, isoforms TCF4-F,
-N and -R contain a region coded by exons 5–6, isoform TCF4-Q
has only a short sequence coded by exon 6, and the rest of the
isoforms (TCF4-D, -G, -A, -H and -I) lack AD1.
Apart from differences in the N-termini, the number of TCF4
isoforms is increased by in-frame alternative splicing of internal
exons (Figures 1C and S1). Firstly, simultaneous skipping of
internal cassette exons 8 and 9 gives rise to TCF4 D isoforms, as
opposed to full-length isoforms that contain the amino acids coded
by exons 8–9. Secondly, at exon 18 there are two alternative splice
donor sites that enable to splice in or out a 12 bps sequence
encoding amino acid sequence RSRS present in + isoforms and
absent in 2 isoforms. Thirdly, exons 8 and 15 contain two
alternative splice acceptor sites that lead to optional inclusion of
the first three nucleotides (CAG) of an exon in mRNA and a
glutamine or alanine residue, respectively, in the corresponding
position in protein sequence (Figure S1). All TCF4 isoforms,
regardless of their N-terminal or internal differences, contain
transactivation domain AD2 (coded by exons 14–16) and the
bHLH domain (coded by exon 19).
The overall structure of TCF4 gene is conserved in the mouse
genome. The identity between human and mouse sequences for
internal exons 3–20 and 39 exon 21 is 92%. Out of the 21 TCF4 59
exons in human genome at least 13 are also transcribed in mouse as
assessed by the presence of respective ESTs in public databases
(Table S1). Sequences of most human 59 exons align to the
respective regioninthe mousegenomewithapproximately 70–99%
identity(Figure S2). Exons1b,3c,5b and 5caremore divergent and
for exons 1a, 1 and 2 no alignment between human and mouse
genes was obtained. Five out of the seven non-conserved human
TCF4 exons indicated above originate from exonization of various
transposable elements. Namely, exon 1a overlaps with two LTR
repeats, exon 1b overlaps with DNA transposon MER5B, exon 1
consists of SINE (Alu) and LINE repeat sequences, exon 2 consists
of Alu repeat sequence and exon 5c consists of SINE (MIR) element
sequence. In addition, 59 exon 3a immediately follows a SINE
(MIR) element in the genome (Figure S2).
In order to determine the relative abundance of mRNAs
initiated at different positions within the TCF4 gene, we carried
out ribonuclease protection assays with the probe spanning
internal exons 3–11 (Figure 2A). Transcripts containing different
number of internal exons were detected in human cerebellum and
muscle (Figure 2B). The longest protected fragment, containing
exons 3–11, corresponds to transcripts initiated at 59 exons 1a, 1b
and 3a–3d. The fragment comprising exons 4–11 represents the
sum of transcripts containing the above mentioned 59 exons in
case of exon 3 skipping and transcripts initiated at 4a–4c. The
fragments comprising exons 5–11, 7–11 and 8–11 rise from
transcripts initiated at 5a–5c, 7a–7b and 8a–8d, correspondingly.
The fragments comprising exons 3–7, 4–7 and 5–7 represent
transcripts that are initiated at the same sites as fragments 3–11,
4–11 and 5–11, respectively, but that lack the cassette exons 8–9 as
a result of alternative splicing. All D8–9 transcripts additionally
give rise to the fragment containing exons 10–11 and this fragment
also includes transcripts initiated at exons 10a–10c. Densitometric
quantification of the protected fragments showed that the levels of
TCF4 transcripts spanning different number of internal exons were
comparable in both human cerebellum and muscle (Figure 2C).
From these data we concluded that transcription is initiated at
relatively similar levels from alternative sites within the TCF4 gene.
TCF4 mRNAs are ubiquitously but not equally expressed
We studied the usage of different 59 exons in a variety of human
tissues and brain regions by reverse transcription polymerase chain
reaction (RT-PCR). Our results showed that although the majority of
the alternative TCF4 transcripts were present in most tissues
analyzed, there were a few that h a dam o r el i m i t e de x p r e s s i o n
pattern (Figure 3A). For instance we detected transcripts containing
exon 1a only in testis, prostate and placenta. The use of 59 exons 1b,
3a and 5c was restricted to testis, prostate and trachea. Furthermore,
there were several transcripts, most remarkably 8d transcripts, that
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PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22138Figure 1. Structure and alternative splicing of the human TCF4 gene. TCF4 genomic organization with (A) introns drawn in scale or (B) exons
drawn in scale. White boxes mark 59 exons and light grey boxes represent internal or 39 exons. Exon names are shown below the boxes. Roman numerals
designate alternative splice donor or acceptor sites. Numbers above the exons indicate their sizes in bps. The regions encoding the respective domains of
TCF4, the NLS identified in this study and the epitope of the used TCF4 antibody are indicated below the gene structure. Locations of RPA and ISH
riboprobes used in this study are also shown. AD, transcription activation domain;bHLH, basic helix-loop-helix domain;NLS, nuclear localization signal;RPA,
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than in other tissues. RT-PCR analysis also provided information
about the occurrence of alternative splicing. The skipping of exon 3
(D3) was a minor event in case of transcripts 1b, 3a, 3c, and 3d,
whereas comparable levels of full-length and D3m R N A sw e r e
present in case of transcripts 1a and 3b. Several general observations
were made concerning the usage of alternative splice donor sites at 59
e x o n s .F i r s t l y ,t h ep r e v a l e n c eo fs p l i c es i t eu t i l i z a t i o na te x o n7 a
decreased in the row of II, III, I. Secondly, the levels of 7b-I
transcripts were higher than those of 7b-II transcripts in most of the
tissues analyzed, except in the nervous system where nearly equal
levels of 7b-I and 7b-II transcripts were detected. Thirdly, 8b-I
transcripts were present only in the cerebellum, whereas in all other
tissues and brain regions splice donor site II of exon 8b was
exclusively used. Fourthly, splice site II was predominantly used at
exon 8c. The levels of 5a and 8c-I transcripts weretoo low for reliable
expression analysis; nevertheless, the respective PCR amplification
products were consistently detected in the brain samples (data not
shown). Our analysis did not reveal the usage of splice donor site II at
exon 4a in any of the tissues studied.
Next, we examined in-frame alternative splicing of TCF4
internal exons (Figure 3B). To monitor the splicing of cassette
exons 8–9, we performed PCR with forward and reverse primers
in exon 5 and 11, respectively. To evaluate the usage of two
alternative splice donor sites at exon 18, we amplified the region
spanning exons 10–20 and analyzed the PCR product by
restriction with BglII, that has a unique recognition site in the
12 bp region present only in transcripts coding for the + isoforms.
As shown in Figure 3B inclusion of exons 8–9 was prevalent and
skipping of exons 8–9 a rare event in most tissues analyzed.
Comparable amounts of full-length and D8–9 transcripts were
present only in the corpus callosum. The levels of transcripts
containing or lacking the extra 12 bps of exon 18 were roughly
equal in most tissues analyzed (Figure 3B).
To compare TCF4 expression levels in different human tissues
more precisely, we performed quantitative PCR with three pairs of
primers designed to amplify all TCF4 transcripts (products
spanning exons 10–11, 17–18 or 19–20). The obtained relative
values were normalized to the expression levels of four house-
keeping genes as described in Materials and Methods. We found
that TCF4 mRNA levels were considerably elevated in fetal brain
and adult cerebellum – approximately 200 and 100 times above
the levels measured in colon, respectively (Figure 4A). Compared
to the levels in colon, about 40-fold higher levels were detected in
cerebral cortex and spleen and more than 10-fold higher levels
were seen in uterus, lung, thymus and placenta. The lowest
quantities of TCF4 transcripts were present in fetal liver, pancreas
and colon. From these results we concluded that although the
expression of TCF4 is ubiquitous, its levels vary considerably
between tissues. Particularly, we turned our attention to high
expression levels of TCF4 in the nervous system and carried out in
situ hybridization experiments on sections from human hippo-
campus and cerebellum to characterize TCF4 expression at
cellular level. As shown in Figure 4B TCF4 mRNA was detected
in hippocampal neurons in dentate gyrus and CA1-CA3 regions,
neurons of subiculum and parahippocampal gyrus of the cortex,
and cerebellar granule neurons.
Several TCF4 protein isoforms are expressed in human
tissues
We next asked whether and which of the different TCF4 protein
isoforms are translated in vivo. To address this question we
monitored the expression of endogenous TCF4 isoforms in
different human tissue extracts by western blotting with TCF4-
specific antibodies that recognize an epitope present in all
described TCF4 isoforms. As shown in Figure 5A multiple
TCF4 isoforms were present in human lung, liver, kidney, muscle
and testis. In these tissues we detected three prominent bands that
were assigned as high, medium and low molecular weight (Mw)
TCF4. In case of frontal cortex, hippocampus and cerebellum low
molecular weight TCF4 band was predominant and the signals of
medium and high Mw TCF4 were very low. The levels of high or
Figure 2. Initiation of transcription from alternative sites
within the TCF4 gene. (A) Schematic representation of the
ribonuclease protection assay probe complementary to TCF4 exons
3–11. Location of the TCF4 59 exons relative to the probe is shown with
arrows and the sites of alternative splicing with lines. (B) Autoradio-
graph of the probe fragments protected by human cerebellum or
muscle RNA and fragments obtained from control reactions with yeast
RNA or without RNase treatment. The expected sizes of the protected
fragments in bps and the exons they span are shown at the left and the
location of the size markers at the right. (C) Densitometric quantifica-
tion of the protected fragments in B from two assays. The values are
given in relation to the levels of the fragment spanning exons 3–11 for
both tissues. Error bars indicate standard deviations.
doi:10.1371/journal.pone.0022138.g002
ribonuclease protection assay; ISH, in situ hybridization. (C) TCF4 alternative transcripts grouped together according to the encoded TCF4 protein isoform.
Translatedanduntranslatedregionsareindicatedasdarkgreyandwhiteboxes,respectively.Transcriptsaredesignatedwiththenameofthe59exon and, if
needed, with the number of the splice site used in the 59 exon. Excluded internal exons are shown with the symbol D a n di n c l u d e di n t e r n a le x o n si n
parentheses, if necessary. The names of the protein isoforms are shown at the right. The isoforms cloned in this study are brought in bold. The position of
the first in-frame start codon for each transcript and stop codon are shown with empty and filled arrows, respectively. Arrowheads at the bottom of the
panel point to the regions of alternative splicing giving rise to full-length (FL) and D, 2 and + isoforms.
doi:10.1371/journal.pone.0022138.g001
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in testis or lung, respectively. To validate the specificity of the
TCF4 antibodies, we implemented a RNAi based approach in
Neuro2A mouse neuroblastoma cells. Similarly to the human
tissue extracts, high, medium and low Mw bands were detected in
the lysates of Neuro2A cells by western blotting with the TCF4
antibodies. Compared to mock and scrambled siRNA transfected
cells the levels of all three forms were reduced in cells transfected
with three different siRNAs targeting TCF4 exon 12 or 20 that are
present in all described TCF4 transcripts (Figure 5B), thus verifying
that the TCF4 antibodies used in the current study specifically
recognize TCF4 proteins.
In order to define the nature of the three bands, we cloned the
coding regions of isoforms TCF4-A – TCF4-I into pCDNA
mammalian expression vector. In addition, we cloned variants
coding for + and 2 isoforms, full-length and D isoforms. We
transfected the obtained plasmids into HEK293 cells and detected
the overexpressed proteins by western blotting with TCF4-specific
antibodies. The different TCF4 isoforms were expressed at
variable levels (Figure 5C). The levels of isoforms TCF4-B
+,
-B
2,- B D
+,- B D
2,- C D
2,- A
+,- A
2,- H
2 and -I
2 were high, those
of TCF4-C
2 and -D
2 medium, and those of TCF4-E
2 and -F
2
low. Expression of TCF4-G
2 was not detected by western blotting.
Although it was not possible to distinguish all isoforms from each
other by size, we compared side by side the bands detected in
human muscle and testis to different TCF4 isoforms translated in
vitro (Figure 5D) and made the following conclusions about the
nature of the three bands in human tissue extracts: the high Mw
TCF4 fractionates similarly to TCF4-B and -C, the medium Mw
TCF4 similarly to TCF4-D, and low Mw TCF4 to TCF4-A and
TCF4-H. In addition, a few proteins with smaller molecular
weight than any of the cloned TCF4 isoforms were detected in
Figure 3. Expression of alternative TCF4 mRNAs in human tissues and brain regions. (A) RT-PCR analysis of TCF4 transcripts with different 59
exons and(B) withalternative internal splicing. Transcripts are designatedas in Figure 1C. The positions of bands respective tothe transcripts encoding the
full-length (FL) and D isoforms, 2 and + isoforms are indicated at the left on panel B. mRNAs with longer exon 18 (+) give rise to RT-PCR product that has a
unique BglIIrestrictionsiteenabling discriminationfrom RT-PCR productsamplified from mRNAs not containingthe 12 bps insert (2). House-keeping gene
SDHA mRNA expression is shown at the bottom of the panel. PCR with no template was performed as a negative control (neg) with each primer pair.
doi:10.1371/journal.pone.0022138.g003
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represent TCF4 proteolytic fragments or undescribed TCF4
isoforms. In sum, the above described TCF4 gene structure and
expression data demonstrate that multiple TCF4 isoforms are
present in human tissues and suggest that the isoforms could
potentially differ in their functional properties.
TCF4 is imported to the nucleus due to its NLS or via a
piggy-back mechanism
To gain insight into possible functional variation amongst the
TCF4 isoforms we first investigated, by indirect immunofluores-
cence, the intracellular localization of TCF4 isoforms overex-
pressed in HEK293 cells (Figure 6A). We observed two patterns of
distribution – exclusively nuclear and nuclear plus cytoplasmic.
Full-length TCF4 isoforms that have longer N-termini (TCF4-B
+,
-B
2,- C
2,- D
2,- E
2,- F
2 and -G
2) were restricted to cell nucleus
whereas isoforms with shorter N-termini (TCF4-A
2,- H
2 and -I
2)
and D isoforms (TCF4-BD
+,- B D
2 and -CD
2) localized to the
nucleus and, in addition, to the cytoplasm.
Since all isoforms with exclusively nuclear distribution contain
the amino acids coded by exons 8–9 and the isoforms with broader
intracellular localization are devoid of these amino acids, we
searched for possible nuclear localization signal (NLS) in this
region. Using PSORT software we identified a potential bipartite
NLS that contains two clusters of basic amino acids (RRR and
KKVRK) separated by a linker of 11 amino acids. The two
clusters are conserved in TCF4 of Mus musculus, Xenopus laevis and
Figure 4. Inter-tissue variability of TCF4 mRNA levels. (A) Quantitative RT-PCR analysis of TCF4 expression in human tissues. Levels of TCF4
transcripts were determined using three different primer pairs and the results were normalized to the expression levels of four house-keeping genes
(SDHA, HMBS, GAPDH and UBC). Shown are the means relative to the TCF4 expression level measured in colon that was arbitrarily set as 1. Error bars
indicate standard deviations. (B) In situ hybridization analysis of TCF4 expression in human hippocampus and cerebellum. Autoradiographs from (a)a
coronal section of the hippocampus and (f) a sagittal section of the cerebellum are shown. Scale bar 1 mm. Bright-field higher magnification images
of emulsion-dipped and hematoxylin-stained sections of (b) the granular cell layer of the dentate gyrus, (c) pyramidal cell layer of the CA2 region, (d)
subiculum and (e) PHG region of the cortex. CA1, CA2, CA3, respective regions of the hippocampus; DG, dentate gyrus; Gr, granular cell layer of the
cerebellum; mol, molecular layer of the cerebellum; PHG, parahippocampal gyrus; S, subiculum.
doi:10.1371/journal.pone.0022138.g004
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(Figure 6B). To validate the NLS we performed site-directed
mutagenesis in the context of TCF4-B
2 isoform and replaced the
basic amino acids in cluster 1, 2 or both with alanines. As shown in
Figure 6C mutagenesis of either cluster 1 (M1) or 2 (M2) produced
a protein that is partly cytoplasmic, but even when both clusters
were mutated (M1+2) a substantial portion of the protein
remained nuclear, similarly to the genuine TCF4 isoforms not
containing the region coded by exons 8–9. As a next step we fused
the NLS to the C-terminus of EGFP and monitored its localization
in HEK293 cells. EGFP-NLS fusion protein was confined to the
nucleus whereas control EGFP was distributed diffusely all over
the cell (Figure 6D). From these results we concluded that the
identified NLS is functional, but additional region(s) responsible
for nuclear import of isoforms lacking the amino acids coded by
exons 8–9 exist in TCF4 protein.
Another region with high basic charge density is located in the
DNA-binding domain of TCF4. To test whether this part of the
protein is able to mediate nuclear import we constructed different
fusion proteins where the entire bHLH domain or its N-terminal
or C-terminal part is fused with EGFP. The fusion proteins were
overexpressed in HEK293 cells and their localization was studied
by direct EGFP fluorescence (Figure 6D). EGFP-bHLH was
present in the nucleus and cytoplasm indicating that the bHLH
domain was to some extent able to direct the protein to the
nucleus, since in contrast to EGFP (29 kDa), the EGFP-bHLH
(43 kDa) fusion protein cannot be transported to the nucleus by
passive mechanisms due to its higher molecular mass. At the same
time EGFP-bHLH-N (36 kDa) and EGFP-bHLH-C (37 kDa)
were detected only in the cytoplasm, meaning that neither part
alone was able to mediate nuclear import. These data led us to
hypothesize that structural integrity of the bHLH domain is
necessary for EGFP-bHLH nuclear localization mediated by
heterodimerization with endogenous NLS bearing HLH-proteins.
To test this assumption, we co-expressed EGFP and the described
fusion proteins together with known TCF4 dimerization partners:
E2-tagged NeuroD2 (Gene 18013), that features nuclear localiza-
tion, and mCherry-fused Id2 (Gene 15902), that bears a nuclear
export signal (NES) and is similarly to the described EGFP-Id2
fusion protein [29] predominantly cytoplasmic. The results of this
assay showed that NeuroD2-E2 did not influence the distribution
of EGFP and EGFP-bHLH-N, but was able to direct EGFP-
bHLH and to lesser extent also EGFP-bHLH-C to the nucleus.
Co-expression of mCherry-Id2 altered only the localization of
EGFP-bHLH by excluding it from the nucleus (Figure 6D). We
additionally monitored the effects of NeuroD2-E2 and mCherry-
Id2 co-expression on the localization of genuine NLS-lacking
TCF4 isoform A
2. Similarly to EGFP-bHLH, the distribution of
TCF4-A
2 was guided by its heterodimerization partner
(Figure 6E). Altogether these results demonstrate that TCF4 can
be directed to the nucleus by two mechanisms. Firstly, isoforms
that bear the NLS independently translocate to the nucleus.
Secondly, all TCF4 isoforms can be transported to the nucleus by
a piggy-back mechanism through heterodimerization with NLS
containing bHLH partners. Additionally, isoforms lacking NLS
can be exported from the nucleus by heterodimerization with NES
containing partner proteins.
Subsequently, we examined the intracellular distribution of
endogenous TCF4. For this we chose to study human hippocam-
pus and cerebellum because of high TCF4 expression levels in
these brain regions. We performed immunohistochemical staining
of the sections using TCF4 and neuronal marker NeuN or glial
marker GFAP specific antibodies, followed by confocal microsco-
py. As shown in Figure 6F, TCF4 signal was found mainly in the
neuronal nuclei but also in the cytoplasm of neurons in different
hippocampal regions (CA, dentate gyrus, hilus) and cerebellar
granular layer. Of note, the TCF4 antibody additionally marked
processes of GFAP-positive cells in tissues and rat primary
cultures, but to our knowledge this glial cytoplasmic signal is
non-specific as no such staining was observed when tagged TCF4
isoforms were overexpressed in cultured rat glial cells and stained
with tag-specific antibodies (data not shown).
TCF4 isoforms activate transcription differentially
As a next step in functional characterization of TCF4 isoforms
we performed reporter assays with a construct carrying 12 mE5
(CACCTG) E-boxes [1] in front of a minimal promoter
controlling the expression of firefly luciferase gene luc2P
(Figure 7A). The reporter construct was transfected into
HEK293 cells together with expression plasmids encoding
different TCF4 isoforms and a vector with the minimal promoter
in front of Renilla luciferase hRlucP gene. Compared to empty
vector transfected cells the normalized luciferase activity was
approximately 250 or 150 times higher in cells expressing TCF4-
Figure 5. Expression of TCF4 protein isoforms. (A) Western blot analysis of different human tissues and brain regions with TCF4 antibodies. (B)
The effect of TCF4 targeting siRNAs on the levels of proteins detected by TCF4 antibodies in extracts of Neuro2A cells. Three different siRNAs specific
for TCF4 exon 12 or 20 were transfected into Neuro2A cells; mock and scrambled siRNA transfections were performed in control. Tubulin b levels were
determined to demonstrate equal loading. (C) Western blot analysis of TCF4 isoforms overexpressed in HEK293 cells using TCF4 antibodies. (D)
Comparison of fractionation of proteins recognized by TCF4 antibodies in human muscle and testis extracts to in vitro translated selected human
TCF4 isoforms. The localization of endogenous TCF4 with high, medium or low molecular weight is indicated at the left in A, B and D; the dashed line
in C and D separates different exposures; molecular mass (in kDa) marker bands are shown at the right on all panels.
doi:10.1371/journal.pone.0022138.g005
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+ or -B
2, respectively. More than 650-fold increase was observed
with TCF4-B D
+ and -B D
2 isoforms. TCF4-C
2 activated
reporter gene transcription over 10 and TCF4-C D
2 almost 50
times. The increased luciferase activity in D isoforms expressing
cells compared to the respective full-length isoform expressing cells
could reflect higher levels of D isoforms in HEK293 cells
(Figure 5C). The two isoforms with low expression level, TCF4-
E
2 and -F
2, activated reporter gene transcription about 7- and
21-fold, correspondingly. Isoforms completely lacking AD1
elevated luciferase activity approximately 20 (TCF4-D
2,- A
+ and
-A
2) or 70 times (TCF4-H
2 and -I
2). Search for correlations
revealed a strong positive relationship between the presence of full-
length AD1 and isoform’s ability to transactivate in HEK293 cells
(point biserial correlation coefficient r=0.87, p,0.00011). There
were no significant correlations between the isoform’s capacity to
activate transcription and the presence of NLS, presence of only
the C-terminal part of AD1 or presence of the extra four amino
acids in the + isoforms. These results indicate that, although to a
different extent, all TCF4 isoforms analyzed are able to activate
transcription controlled by mE5 E-boxes in HEK293 cells.
To study further the individual role of TCF4 transcription
activation domains AD1 and AD2, we took two approaches.
Figure 6. TCF4 intracellular localization. (A) Immunocytochemical analysis of V5-tagged TCF4 isoforms overexpressed in HEK293 cells. Isoforms
analyzed are indicated at the top and localization pattern at the bottom of the panel. n, nuclear; c, cytoplasmic; n+c, nuclear and cytoplasmic. DNA
was counterstained with DAPI (pseudocoloured red) to visualize nuclei. (B) Alignment of the identified bipartite NLS in TCF4 of Homo sapiens (h), Mus
musculus (m), Xenopus laevis (x) and Danio rerio (d); in E2A and HEB of Homo sapiens. Two clusters of basic amino acids (in red, 1 and 2) and the linker
are indicated with lines at the top. Conservation is indicated at the bottom. ‘*’, identity; ‘:’, conserved; ‘.’, semi-conserved substitution. (C) The effect
of site-directed mutagenesis of the NLS on the localization of TCF4 in HEK293 cells. Basic amino acids in cluster 1 (M1), 2 (M2) or both (M1+2) were
replaced with alanines in the context of TCF4-B
2-V5 and the localization of the proteins was monitored by immunocytochemistry. (D) Localization of
EGFP fusion proteins with TCF4 NLS, bHLH, N-terminal (N) or C-terminal (C) half of TCF4 bHLH domain in HEK293 cells. NeuroD2-E2 or mCherry-Id2
encoding plasmid was cotransfected when indicated. White arrows indicate cells expressing mCherry-Id2. (E) Effect of mCherry-Id2 or NeuroD2-E2 co-
expression on subcellular distribution of TCF4-A
2. The localization patterns of overexpressed TCF4 proteins are indicated at the right of the panels in
C, D and E. (F) Immunohistochemical analysis of endogenous TCF4 in human hippocampal and cerebellar sections. NeuN staining was used to
identify neurons.
doi:10.1371/journal.pone.0022138.g006
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2 without
AD2 (DAD2) and native TCF4-A
2 to regulate E-box controlled
transcription. TCF4-B
2 DAD2 contains the AD1 and TCF4-A
2
the AD2 domain, both have the bHLH domain. Secondly, we
used heterologic constructs where AD1 or AD2 is fused with
GAL4 DNA binding domain and E2 epitope-tag. We assessed the
ability of the GAL4 fusion proteins to activate reporter
transcription from pG5luc vector that carries GAL4 binding sites
in front of firefly luciferase luc gene. As shown in Figures 7B and
7C similar reporter gene activation levels were achieved with
TCF4-B
2 DAD2 compared to TCF4-A
2, and GAL4-AD1-E2
compared to GAL4-AD2-E2 in HEK293 cells. When joined to
native bHLH DNA binding domain, 24 or 18 fold upregulation of
reporter gene transcription were seen with AD1 or AD2
containing proteins, respectively (Figure 7B) When fused with
heterologic GAL4 DNA binding domain, AD1 activated tran-
scription about 10 times and AD2 about 24 times (Figure 7C). We
noted that when both activation domains are present in a single
Figure 7. Transcription activation by alternative TCF4 isoforms. (A) Reporter assay with HEK293 cells transfected with firefly luciferase
construct carrying 12 mE5 E-boxes in front of a minimal (min) promoter along with the indicated TCF4 isoform encoding plasmid or an empty vector.
(B) Reporter assay with HEK293 cells transfected with luciferase constructs and TCF4-B
2DAD2 or TCF4-A
2 encoding plasmid or empty vector as
indicated. (C) Reporter assay with HEK293 cells transfected with firefly luciferase construct carrying 5 GAL4 binding sites (GBS) in front of adenovirus
major late promoter (AV MLP) along with the indicated E2-tagged GAL4 fusion proteins. (A, B and C) For normalization Renilla luciferase construct
with minimal promoter was cotransfected. Luciferase activities were measured and data are presented as fold induced levels above the signals
obtained from empty vector transfected cells. Shown are the mean results from at least three independent experiments performed in duplicates,
error bars indicate standard deviations. Statistical significance shown with asterisks is relative to the luciferase activity measured from empty vector
transfected HEK293 cells (*, p,0.05; **, p,0.01; ***, p,0.001; t-test). RLU, relative luciferase units. Schematic representation of the expressed TCF4
proteins with the locations of restriction enzymes used for the generation of the respective plasmids is shown at the left. (D) Western blot analysis of
TCF4-B
2DAD2 and TCF4-A
2 expressed in HEK293 cells. (E) Western blot analysis of E2-tagged GAL4 fusion proteins expressed in HEK293 cells. (D and
E) Localization of molecular mass (in kDa) marker bands is indicated at the bottom and the order of samples is as in B and C, respectively.
doi:10.1371/journal.pone.0022138.g007
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transcription exceeds the additive effect of AD1 and AD2,
suggesting that the two domains may act synergistically in
HEK293 cells. To test this we studied the transactivation capacity
of GAL4 fusion proteins that contain both TCF4 activation
domains joined by native or heterologic amino acids. As shown in
Figure 7C these proteins activated reporter transcription approx-
imately 100 and 50 times, respectively. In both cases the activation
fold exceeded the additive effect of single TCF4 activation domain
containing GAL4 fusion proteins. All the compared proteins were
expressed at similar levels in HEK293 cells as determined by
western blotting with TCF4 or E2-specific antibodies (Figures 7D
and 7E). Altogether these data show that the two activation
domains are capable of mediating transactivation to a similar
extent in HEK293 cells. Additionally, the results indicate that
when both activation domains are present in a single protein, the
two domains act synergistically in HEK293 cells.
Discussion
Large-scale human transcriptome analyses have revealed that
more than 90% of protein-coding genes undergo alternative
splicing and around half have two or more alternative promoters
[26,30–32]. Additionally, over-representation of alternative pro-
moters has been attributed to genes involved in development and
regulation of transcription [32]. Here, we demonstrate that the
human gene for the transcription factor TCF4 is transcribed using
21 mutually exclusive 59 initial exons, many of which contain more
than one transcription start sites and/or splice donor sites. These
59 exons are located at various positions in the gene interspersed
with internal exons 1–9, followed by constitutive internal exons
10–20 and 39 exon 21. Therefore, TCF4 transcripts containing
different number of internal exons are generated and, according to
our data, these are expressed at comparable levels in human
tissues and potentially encode for TCF4 protein isoforms with 18
different N-termini. We named the isoforms TCF4-A – TCF4-R
in agreement with the previous studies that have described three
N-terminally distinct isoforms, i.e. TCF4-A, -B and -D [2,18].
Additionally, several studies have described TCF4 isoforms
differing by the presence or absence of four amino acids (RSRS)
N-terminal to the bHLH domain [2,18,33,34], which are denoted
here as + and 2 isoforms, respectively. These isoforms result from
alternative splice donor site selection at exon 18 and their mRNAs
are present at comparable levels in most human tissues analyzed
here. We show that in human TCF4 gene there is another site of
alternative splicing at internal exons 8–9. Transcripts lacking these
exons are expressed at low levels in human tissues and code for
protein isoforms indicated with D in this study.
One by one analysis of alternative 59 exons containing TCF4
transcripts’ expression and quantitative analysis of overall TCF4
expression in human tissues corroborated the concept of TCF4
being a ubiquitous transcription factor. Most alternative 59 exons
containing transcripts were broadly expressed. Nevertheless,
expression of transcripts containing 59 exons 1a, 1b, 3a and 5c
was detected only in a few tissues including testis and prostate.
These exons originate from exonization of different transposable
elements (TEs) or are located immediately behind a TE in the
human genome. Incorporation of TE-derived sequences into
promotersorUTR orcodingregions ofgeneshasbeen documented
by many studies [35–37]. In accordance with the restricted
expression of TE-dependent TCF4 transcripts, TEs are known to
be transcriptionally silenced in most mammalian tissues as a defense
mechanism against potentially deleterious effects of their activity
[38,39]. TE-dependent TCF4 transcripts code for 5 unique TCF4
protein isoforms with long N-termini (TCF4-J – TCF4-N). Since it
wasnotpossibletodistinguishall TCF4isoformsfrom each otherby
SDS-PAGE fractionation, we were not able to conclusively
determine which protein isoforms are expressed in human tissues;
nevertheless, we detected three prominent TCF4 forms of different
molecular weight. Notably, high Mw TCF4 protein was relatively
more abundant in testis, medium Mw TCF4 in lung and low Mw
TCF4 was the major form in the brain tissue, insinuating that the
ratio of different TCF4 isoforms with distinct N-termini is varied
between human tissues.
Our report reveals that although broadly expressed, TCF4
transcript levels differ greatly between tissues. The highest levels
are present in fetal brain, but expression remains elevated also in
adult brain where we detected TCF4 mRNA and protein in
neurons. These findings are consistent with earlier studies that
have demonstrated TCF4 expression in human or rodent nervous
system [18,40–44] and further support the important role for
TCF4 in the development and functioning of the nervous system
as exemplified by involvement of TCF4 in the pontine nucleus
development in mice, association of TCF4 with schizophrenia and
identification of TCF4 haploinsufficiency as the cause of Pitt-
Hopkins mental retardation syndrome [17,21–24]. Interestingly,
translocation that results in a TCF4 allele without at least 6 upper
59 exons has been described in a patient with mild mental
retardation [45]. Possibly, in this patient, initiation of TCF4
transcription at downstream 59 exons still takes place, explaining
the less severe phenotype than in classical Pitt-Hopkins syndrome
patients. Nevertheless, it seems that for production of sufficient
amounts of TCF4 protein and normal development, the presence
of all transcription initiation sites is critical. Based on experiments
with HEB and E2A knockout mice, it has been suggested that the
overall E-protein dosage is more crucial in the development of
nervous system than family member identity [46]. However, since
even slight disturbances in TCF4 expression in human cause a
neurodevelopmental disorder and TCF4 knockout mice display
disrupted pontine nucleus development [17], it is apparent that
other E-proteins are not able to compensate for the loss of TCF4
in all aspects of the nervous system development. Additionally,
transgenic mice with mild overexpression of TCF4 in forebrain
display deficits in contextual and cued fear conditioning and
sensorimotor gating [47], indicating that precise regulation of
TCF4 expression is crucial for correct brain function and
deviations in either way result in cognitive disturbances. All this
substantiates the complex structure and the high number of 59
exons in TCF4 gene, as these probably enable proper amounts of
TCF4 protein to be synthesized. It is noteworthy that according to
the TCF4 gene structure described here, the SNP rs9960767
associated with susceptibility to schizophrenia [21] is located in
TCF4 intronic sequence between 59 exons 5b and 5c. However,
whether and how this marker is coupled to dysregulation of TCF4
expression remains to be elucidated.
The variety of TCF4 isoforms raises a question – are they
produced only for sufficient amount of TCF4 proteins or are the
functionsofdifferentisoformsdivergent?Inthepresentstudywehave
shown that the alternative TCF4 isoforms differ in two aspects: first,
their intracellular distribution is differentially regulated depending on
the presence or absence of a nuclear localization signal; second, their
ability to activate E-box controlled transcription is varied depending
mainly on whether they contain one or two functional transcription
activation domains. We discovered in the region coded by exons 8–9,
upstream of AD2, a bipartite NLS that is responsible for nuclear
localization of TCF4 isoforms with longer N-termini. This NLS is
conserved among E-proteins and mutating the second half of the
NLS has been demonstrated to reduce nuclear import of E2A [48].
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isoforms do not contain the NLS. Our analysis shows that these
proteins are transported to the nucleus via heterodimerization with
NLS-bearing partners and directed to the cytoplasm by forming
dimers with NES-containing proteins. As substantial amount of NLS-
lacking TCF4 isoforms overexpressed in HEK293 cells is localized to
the nuclei, there must be abundance of NLS-containing hetero-
dimerization partners expressed endogenously. This is not surprising
since TCF4 is able to form dimers with a variety of class B bHLH
factors [3]. In addition, we noticed that NLS-bearing TCF4-B
isoform was not able to mediate nuclear redirection of NLS-lacking
TCF4-A isoform (data not shown), suggesting that TCF4 homodi-
mers are not efficiently formed in HEK293 cells.
E-proteins function as transcription activators or repressors
[49]. In our reporter assays all TCF4 isoforms were able to
activate transcription from a promoter containing mE5 E-boxes in
HEK293 cells whereas TCF4-B isoforms were more potent
transactivators than other isoforms. All the studied isoforms
contain the AD2 domain, but only TCF4-B isoforms contain full-
length AD1, including exon 3 encoded LDFS motif that is known
to be required for AD1 mediated transactivation by recruiting
histone acetyltransferases [50,51]. This motif is present also in
some of the TE-dependent isoforms (TCF4-J, -K, and -L) that
were not included in our reporter assays. We suggest that the AD1
acts synergistically with the AD2, since the additive effect of
individual capacities of these domains to activate transcription is
surpassed by proteins that contain both TCF4 activation domains.
Similar synergism between two activation domains has been
described in bHLH-zipper protein TFE3 and POU homeodomain
protein Oct-2 [52,53]. In contrast to a study on FGF-1 promoter
that proposed differential roles for TCF4 + and 2 isoforms [33],
we saw no differences between the + and 2 isoforms in ability to
activate transcription from mE5 E-boxes controlled promoter.
However, we noticed higher reporter gene transcription in the
presence of D isoforms than the respective full-length isoforms,
probably due to higher expression levels of D isoforms compared
to full-length isoforms. This indicates that NLS coding region
absent in D isoforms could affect the stability of TCF4 proteins. In
sum, we show that differences in the functioning of alternative
TCF4 isoforms do exist. In the light of the knowledge that an
isoform of HEB, homologous to TCF4-A, is specifically required
for the generation of T-cell precursors in vivo and this function
cannot be carried out by the HEB isoform homologous to TCF4–
B [54], it would be of importance to study the distinct functions of
TCF4 isoforms by rescue experiments with different TCF4
isoforms in TCF4 knockout background.
Materials and Methods
Ethics statement
All experiments with human postmortem tissues were approved
by the ethics committee of medical studies at National Institute for
Health Development of Estonia (Permit Number: 402). The
protocols involving animals were approved by the ethics
committee of animal experiments at Ministry of Agriculture of
Estonia (Permit Number: 45).
Bioinformatic analyses
Human TCF4 gene structure and mRNAs were identified by
analyzing genomic, mRNA and expressed sequence tag (EST)
databases using tools available at http://www.ncbi.nlm.nih.gov
and http://genome.ucsc.edu. The locations of transposable
elements were determined by RepeatMasker track in UCSC
Genome browser. Nuclear localization signal (NLS) was predicted
using software at http://wolfpsort.org. Sequence alignments were
prepared with tools available at http://www.ebi.ac.uk/Tools. The
nucleotide sequences have been deposited in the EMBL
Nucleotide Sequence Database under Accession Numbers
FR748202-FR748223.
Constructs
Standard methods of recombinant DNA technology were used
for generation of all constructs. Full-length coding regions of
TCF4 isoforms were PCR-amplified from human brain cDNA
and cloned into pcDNA3.1 (Invitrogen). Both, constructs coding
for native TCF4 and C-terminally V5/His-tagged TCF4 isoforms,
were created. TCF4-B
2 amino acid sequence is used as a
reference for the description of following TCF4 constructs.
pEGFP-C1-C3 (Clontech) were used for generation of pEGFP-
NLS, pEGFP-bHLH, pEGFP-bHLH-N and pEGFP-bHLH-C
that code for EGFP fusion proteins containing TCF4 amino acids
P156-P178, I541-M667, I541-K585 and E586-M667, respective-
ly. Mutagenesis of TCF4 NLS was performed using complemen-
tary primers against the target sequence containing the respective
mutation using Phusion High-Fidelity DNA Polymerase (Finn-
zymes). pcDNA-TCF4B
2DAD2 codes for TCF4-B
2 without
amino acids G316-M497. GAL4 DNA-binding domain was
obtained from pBind vector (Promega) and inserted into pQM-
CMV-E2-C vector (Icosagen). TCF4 activation domains AD1
(M1-Y148), AD2 (G316-G496), AD1–AD2 (M1-G469) and AD1
plus AD2 with heterologic linker (M1-Y148, HLERPGI, G316–
G496) were cloned in-frame between GAL4 DNA-binding
domain and E2-tag. Full-length coding regions of NeuroD2 and
Id2 were PCR-amplified from mouse brain cDNA and inserted
into pQM-CMV-E2-C (Icosagen) in front of E2 tag and
pmCherry-C (Clontech) behind mCherry sequence, respectively.
For E-box reporter vector pGL4.29[luc2P/12 mE5/Hygro], the
CRE binding-site in pGL4.29[luc2P/CRE/Hygro] (Promega) was
replaced with 12 mE5 E-boxes by tandem insertion of annealed
oligonucleotides. For pGL4[hRlucP/min/Hygro], the 12 mE5 E-
boxes were removed from pGL4.29[luc2P/12 mE5/Hygro] and
firefly luciferase encoding luc2P was replaced with Renilla luciferase
encoding hRlucP gene from pGL4.83[hRlucP/Puro] (Promega).
For pBluescript-TCF4(3F-11R) and pSC-A-TCF4(10F-16R) used
for cRNA probe synthesis, PCR amplified TCF4 cDNA fragments
spanning exons 3–11 and 10–16 were ligated into EcoRV
linearized pBluescriptKS+ vector or cloned into pSC-A vector
(Stratagene), respectively. Sequences of all oligonucleotides used
are listed in Supporting Table S2.
Ribonuclease protection assay
EcoRI linearized pBluescript-TCF4(3F-11R) was subjected to in
vitro transcription using MAXIscript Kit and T3 polymerase
(Ambion). The concentration of limiting nucleotide (UTP) was
10 mM of which 1/6 was [a-
32P]UTP (specific activity 3000 Ci/
mmol; Hartmann analytics). 10 mg of total RNA and 2.5610
5
CPM of radiolabeled probe were used for hybridization and the
assay was performed with the RPA III Kit (Ambion) as suggested
by the manufacturer. The protected fragments were separated in
5% acrylamid urea gel, visualized by autoradiography and
quantified with ImageQuant T4 software (Amersham Biosciences).
RNA isolation and RT-PCR
Total RNAs from postmortem adult human brain regions and
muscle were purified using RNAwiz reagent (Ambion) and treated
with TURBO DNase (Ambion). Other human tissue RNAs were
obtained from Clontech. First-strand cDNAs were synthesized from
5 mg of total RNA with Superscript III reverse transcriptase
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recommendations. PCR amplification was performed using HotFire
polymerase (Solis Biodyne). For quantitative PCR, LightCycler 2.0
engine (Roche), qPCR Core kit for SYBR R Green I No ROX
(Eurogentec) and polycarbonate qPCR capillaries (Bioron) were used.
The reactions were carried out in a volume of 10 ml containing 1/80
of reverse transcription reaction as a template. In control, PCR with
primers specific for the ubiquitously expressed hypoxanthine-guanine
phosphoribosyltransferase (HPRT), succinate dehydrogenase com-
plex subunit A (SDHA), ubiquitin C (UBC), hydroxymethylbilane
synthase (HMBS) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were performed. For normalization of quantitative PCR
data the geometricmeanof four selected housekeeping genes (SDHA,
UBC, HMBS and GAPDH) with high expression stability (M,1.5)
was calculated using geNorm software [55]. For quantification of
TCF4 mRNA expression, three different primer pairs detecting all
TCF4 transcripts were designed (products spanning exons 10–11, 17–
18 and 19–20). The results obtained with each primer pair were
normalized with the geNorm calculated factor, log-transformed and
standardized as described [56]. Means and standard deviations (SD)
were calculated and the data were back-transformed to the original
scale for graphical representation. The bars represent geometric
means and error bars represent upper and lower limits back-
transformed as mean+SD and mean–SD, respectively. All products
from the RT-PCR reactions were verified by sequencing. The
primers together with the used annealing temperatures, cycle
numbers and product sizes are listed in Supporting Table S2. When
indicated PCR amplified DNA was diluted three times and subjected
to restriction with BglII (Fermentas).
In situ hybridization
cRNA probes were synthesized from BamHI linearized pSC-A-
TCF4(10F-16R) with MAXIScript in vitro Transcription Kit and
T3 polymerase (Ambion), using [a-
35S]UTP (Amersham Biosci-
ences) for labeling. Serial coronal sections (16 mm) from fresh-
frozen adult male human hippocampus and cerebellum were
subjected to in situ hybridization following the protocol described
earlier [57]. Emulsion-dipped sections were developed after 3
weeks using D-19 developer (Eastman Kodak), fixed (sodium fixer;
Kodak), and counterstained with hematoxylin (Shandon).
Cell culture and transfection
Human embryonic kidney HEK293 cells and mouse neuro-
blastoma Neuro2A cells were grown in MEM (Minimum Essential
Medium Eagle; PAA) or DMEM (Dulbecco’s modified Eagle’s
medium; PAA), respectively, supplemented with 10% fetal bovine
serum (PAA), 100 U/ml penicillin (PAA) and 0.1 mg/ml strepto-
mycin (PAA) at 37uCi n5 %C O 2. For transfection of DNA
constructs 0.375 mg DNA and 0.75 ml of LipoD293 reagent
(SignaGen) were used per well of a 48-well plate or scaled up
accordingly. In case of cotransfections, equal amounts of all
plasmids were used. For transfection of siRNAs 24 pmol siRNA
and 4 ml of Lipofectamine RNAiMAX (Invitrogen) were used per
well of a 6-well plate. siRNAs were ordered from Ambion and
their sequences are brought in Supporting Table S2.
Protein extracts and Western blotting
In vitro translation was performed using TnT Quick Coupled
Transcription/Translation System (Promega) according to man-
ufacturer’s instructions. Cell and tissue extracts were prepared in
RIPA buffer (50 mM Tris HCl pH 8.0, 150 mM NaCl, 1% NP-
40, 0.5% Na-DOC, 0.1% SDS, 1 mM DTT, 1 mM PMSF,
protease inhibitors cocktail Complete (Roche)). Protein concen-
trations were determined using BCA assay (Pierce). Equal amounts
of proteins were separated in 8% SDS-PAGE and transferred to
PVDF membrane (Biorad). For western blotting the antibodies
were diluted in 2% skim milk and 0.1% Tween 20 in PBS as
following: rabbit polyclone anti TCF4/ITF2 (CeMines) 1:1000,
mouse monoclone anti E2 (Icosagen; 5E11) 1:5000, mouse
monoclone anti tubulin b (Developmental Studies Hybridoma
Bank) 20 ng/ml, HRP-conjugated goat anti mouse/rabbit IgG
(Pierce) 1:5000. Chemiluminescent signal was detected using
SuperSignal West Femto Chemiluminescent Substrate (Pierce).
Cyto- and histochemical immunostaining
For cytochemistry, cells were grown on poly-L-lysine (Sigma)
coated coverslips and fixed with 4% paraformaldehyde for
15 minutes, treated with 50 mM NH4Cl in PBS for 10 minutes
and permeabilized in 0.5% Triton X-100 in PBS for 15 minutes.
Cells were blocked with 2% bovine serum albumin (BSA) in PBS.
The reactions with primary and secondary antibodies were carried
out in 0.2% BSA and 0.1% Tween 20 in PBS at room
temperature. For histochemistry, 16 mm coronal sections from
fresh-frozen adult male human hippocampus and cerebellum were
fixed with 4% paraformaldehyde for 30 minutes and blocked in
0.25% Triton X-100, 0.5% Tween 20, 3% goat serum in PBS.
Primary antibody reactions were carried out in blocking buffer
overnight at 4uC. The antibodies were diluted as following: rabbit
polyclone anti TCF4/ITF2 (CeMines) 1:200, mouse monoclone
anti V5 (Invitrogen) 1:500, mouse monoclone anti E2 (Icosagen,
5E11) 1:500, mouse monoclone anti NeuN 1:100 (Chemicon),
mouse monoclone anti GFAP 1:800 (Chemicon), Alexa 488 or
Alexa 568 conjugated goat anti mouse/rabbit IgG (Molecular
Probes) 1:2000. The samples were mounted in ProLong Gold
antifade reagent with DAPI (Molecular Probes) and analyzed by
confocal microscopy (LSM Duo, Zeiss).
Luciferase assays
Cells on 48-well plates were lysed 24 hours post-transfection in
50 ml Passive Lysis Buffer (Promega). Dual-Glo Luciferase assay
(Promega) was performed following manufacturer’s instructions
and luminescence was measured with GENios pro (Tecan) plate
reader. For data analysis background signals from untransfected
cells were subtracted and firefly luciferase signal values were
normalized to Renilla luciferase signals. The obtained data were
log-transformed, autoscaled, means and standard deviations (SD)
were calculated and t-tests for analyses of statistical significance
were performed. For graphical representation, the data were back-
transformed to the original scale. Error bars represent upper and
lower limits back-transformed as mean+SD and mean–SD,
respectively. Correlation analysis was performed with tools at
http://faculty.vassar.edu/lowry/pbcorr.html.
Supporting Information
Figure S1 Alignment of TCF4 isoforms. Amino acids different
from the consensus are in blue. Localization of functional domains is
indicated with lines above the sequence. Amino acid(s) in parentheses
are absent from (1) isoforms coded by transcripts spliced at acceptor II
of exon 8, (2) D isoforms coded by transcripts without exons 8–9, (3)
isoforms coded by transcripts spliced at acceptor II of exon 15, (4) 2
isoforms (as opposed to + isoforms) coded by transcripts spliced at
donor I of exon 18. AD, activation domain; NLS, nuclear localization
signal; bHLH, basic helix-loop-helix domain.
(PDF)
Figure S2 Multiple alignment of Homo sapiens (h) genomic DNA
regions containing TCF4 59 exons and internal exons 1–2 with the
respective regions in Pan troglodytes (c), Mus musculus (m), Rattus
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are given above each aligned region. The nucleotides in the
aligned regions are numbered according to human genome
assembly March 2006 NCBI36/hg18, chimp genome assembly
March 2006 CGSC 2.1/panTro2, mouse genome assembly July
2007 NCBI37/mm9, rat genome assembly November 2004
Baylor 3.4/rn4 and rhesus genome assembly January 2006
MGSC merged 1.0/rheMac2. Alignments were produced with
ClustalW and the percentages of identity were calculated between
human TCF4 59 exon sequence and the respective mouse
sequence using Needleman-Wunsch global alignment. The exon
sequences are in bold case, internal exons are in blue and
sequences of primers used for expression analysis are underlined.
Dotted blue lines above the sequences indicate transposable
elements. Arabic numerals above exonic sequences indicate the
number of human ESTs starting at the respective position and
obtained from oligo-cap, cap-trapping and SMART libraries
available in public databases through UCSC genome browser as of
3rd of November 2010. Possible in-frame translation start codons
are shaded in gray. For each in-frame ATG codon NetStart
translation start score is shown above the start codon. When
needed the locations of alternative splice donor sites are indicated
with blue roman numerals above the first intronic nucleotides (or
above the first internal exon nucleotides in case of exon 7b-II).
(PDF)
Table S1 Accession numbers of representative mRNA or EST
sequences for alternative TCF4 transcripts and complete coding
sequences of TCF4 isoforms cloned in full-length in this study.
(PDF)
Table S2 List of oligonucleotides used in this study.
(PDF)
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